In September, the US Drug Enforcement Administration reclassified it from Schedule I to Schedule V— the lowest restriction classification available under federal law. Physicians, at their discretion, may also elect to prescribe the medicine “off-label” for medical conditions other than epilepsy.
An annual prescription for Epidiolex is estimated to cost $32,500 per year, a price that the manufacturer says is “in line with other FDA-approved anti-epileptic drugs.”
Epidiolex is the fourth marijuana-based medicine to receive FDA approval — joining dronabinol (aka Marinol), nabilone (aka Cesamet), and liquid synthetic THC (aka Syndros).
However, Epidiolex is the first FDA-approved medicine containing plant-derived non-synthetic cannabinoids.